[x] (Amendment No. 1)
Filed by the Registrant [x]
[ ] Filed by a Partyparty other than the Registrant [ ]

Check the appropriate box:
[ ]x] Preliminary Proxy Statement
[ ] Confidential, For Usefor use of the Commission Onlyonly (as permitted by Rule 14a-6(e)(2))
[x] ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Under Rule 14a-12under s. 240.14a-12

Payment of Filing Fee (Check the Appropriate Box)appropriate box):
[x] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)1. Title of each class of securities to which transaction applies:
(2)2. Aggregate number of securities to which transaction applies:
(3)3. Per unit price of other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)4. Proposed maximum aggregate value of transaction:
(5)5. Total fee paid:
[ ] Fee paid previously with preliminary materials:
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
(1)1. Amount previously paid:
(2)2. Form, Schedule or Registration Statement No.:
(3)3. Filing Party:
(4)4. Date Filed:

To the Shareholders of Medical Information Technology, Inc.:

The 2018 Annual MeetingA special meeting (the "Special Meeting") of Shareholdersshareholders of Medical Information Technology, Inc. ("MEDITECH") will be held on [DATE] at its corporate office, 1 Constitution Way, Foxborough, Massachusetts 02035, on Monday, April 23, 2018 at 8:30am9:00am for the following purposes:purpose:

Shareholders may visit our webpage at www.meditech.com/shareholder/reports.html to access the Proxy Statement, the Proxy Page, the 20172019 audited Annual Report on Form 10-K, 2020 unaudited quarterly reports on Form 10-Q, and other SEC filings.filings, which are also available at www.sec.gov.

Shannon M. Connell, Secretary
Westwood, Massachusetts
March 23, 2018[DATE]

GENERAL INFORMATION

This Proxy Statement is being furnished to shareholders in connection with the solicitation of proxies by the Board of Directors (the "Board") of Medical Information Technology, Inc. ("MEDITECH") for use at the 2018 Annual Meetinga special meeting of Shareholdersshareholders of MEDITECH (the "Special Meeting") to be held on [DATE] at its corporate office,9:00am for the following purpose:

Due to the public health impact of the coronavirus outbreak (COVID-19), the Special Meeting will be held in a virtual meeting format only. You will not be able to attend the Special Meeting in person. You will be able to attend the Special Meeting virtually by visiting https://shareholder.meditech.com. MEDITECH encourages you to access the Special Meeting before the start time of 9:00am on Monday, April 23, 2018[DATE]. Please allow ample time for online check-in, which will begin at 8:30am, and any adjournments or postponements thereof (the "Annual Meeting"),45am on [DATE].

You may submit your proxy by following the instructions provided on the Proxy Page for the purposes set forthSpecial Meeting. We hope you will participate in the attached Formal NoticeSpecial Meeting. Even if you anticipate attending the virtual meeting, we urge you to please vote your proxy either by mail or over the Internet in advance of the 2018 Annual Meeting.

The Board of Directors has fixed the close of business on March 23, 2018[DATE] as the record dateRecord Date for the determination of Shareholders of MEDITECH's common stockdetermining shareholders entitled to receive notice of, and to vote at or before, the Annual MeetingSpecial Meeting. There were 37,190,854 shares of MEDITECH common stock, par value $1.00 per share, issued and any adjournments or postponements thereof (the "Record Date"). Asoutstanding as of the Record Date, there were 37,190,854and 1,813 shareholders of record owning such shares of common stock issued and outstanding, and each such share is entitled to one vote on each proposal presented at the Annual Meeting.

vote. This Proxy Statement and the enclosed Proxy Page along withare being mailed to our shareholders on or about [DATE].

The Reverse Stock Split is considered a "going private" transaction as defined in Rule 13e-3 promulgated under the Exchange Act because it is intended to, and, if completed, will enable MEDITECH to terminate the registration of its Common Stock under the Exchange Act and suspend its duty to file periodic reports and other information with the SEC thereunder.

Cost Savings. The costs of being a public reporting company are significant and have increased over the years, including as a result of compliance with the internal control assessment and audit requirements of Section 404 and other requirements imparted by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act. These and other requirements increase audit fees and other costs of compliance, such as outside securities legal counsel fees, as well as outside director fees and insurance premiums to cover potential liability faced by our officers and directors. We also incur substantial indirect costs as a result of, among other things, our management's time expended to prepare and review our public filings.

A quorum of Shareholdersshareholders is necessary to hold a valid AnnualSpecial Meeting. A majority of the outstanding shares, virtually present in person or represented by proxy, constitutes a quorum. If you have returned a properly signed Proxy Page, you will be considered present at the meeting and part of the quorum. Abstentions arewill be counted as shares present at the meetingSpecial Meeting in determining whether a quorum exists.

This solicitationApproval of proxies for usethe Reverse Stock Split will require an affirmative vote of the holders of a majority of the outstanding shares of Common Stock. As of the Record Date, MEDITECH's Directors and Executive Officers as a group beneficially owned approximately 52% of the outstanding Common Stock. To MEDITECH's knowledge, all such Directors and Executive Officers intend to vote in favor of the Reverse Stock Split at the Annual MeetingSpecial Meeting.

The MEDITECH Board of Directors has carefully considered and unanimously determined approval of the Reverse Stock Split is being made byin the Board. The cost of soliciting proxies will be borne by MEDITECH. Proxies may be solicited, in person or by telephone, by Officers and regular employeesbest interests of MEDITECH who will receive no compensation for their services other than their normal salaries.and its shareholders. Accordingly, MEDITECH's Board of Directors recommends that shareholders approve the amendment to the Articles of Organization and the Reverse Stock Split.

VOTING OF PROXIES

You cannot attend the Special Meeting in person. You can vote on matters which come beforeyour proxy either over the Annual Meeting either by signing and returning the enclosed Proxy PageInternet or by coming tomail in advance of the Annual Meeting and voting by ballot there.

If you sign and return the Proxy Page, theSpecial Meeting. The two individuals named as proxies in the Proxy Page will vote your shares following your directions.as you indicate. If you submit an executed Proxy Page but do not make specific choices,indicate "approve", "disapprove" or "abstain", the proxies will vote "abstain" as your shares for the election of each of the nominees for Director and for the ratification of the selection of Wolf & Company as MEDITECH's Independent Registered Public Accounting Firm for 2018. If anyvote. No other matters are presented for action atwill be voted on other than the Annual Meeting,amendment to the proxies will vote your shares in their discretion.Articles of Organization to effect the Reverse Stock Split. At the time this Proxy Statement was prepared, the Board of Directors knew of no matters to be voted on at the AnnualSpecial Meeting other than those discussed in this Proxy Statement.

You may revoke your proxy after you have signed and returned it at any time before the proxy is voted at the AnnualSpecial Meeting. There are three ways to revoke your proxy: (1) you may send in another Proxy Page with a later date; (2) you may notify MEDITECH's Secretary in writing before the AnnualSpecial Meeting that you have revoked your proxy; or (3) you may vote in personelectronically by ballot at the AnnualSpecial Meeting.

Whether or notEven if you plananticipate attending the virtual meeting, we urge you to attend the Annual Meeting in person, please complete, sign and date the enclosed Proxy Page and return it promptly. If you do attend the Annual Meeting, you may vote your proxy either by mail or over the Internet in advance of the Special Meeting to ensure that your shares will be represented. Due to the expected attendance and virtual nature of the meeting, we encourage you to email your questions to the Secretary before the meeting by ballot even though you have sent in your Proxy Page. However, simply attending the Annual Meeting will not revoke your proxy if you do not vote by ballotemailing sconnell@meditech.com. Please email questions early to ensure a timely response.

This solicitation of proxies for use at the Annual Meeting.Special Meeting is being made by the Board. The cost of soliciting proxies will be borne by MEDITECH. Proxies may be solicited, by e-mail or by telephone, by employees of MEDITECH, who will receive no compensation for their services other than their normal salaries.

The Board(i) audited financial statements of Directors has nominated A. Neil Pappalardo, Lawrence A. Polimeno, Howard Messing, Edward B. Roberts, Barbara A. ManzolilloMEDITECH for the years ended December 31, 2018 and Stuart N. Lefthes for election as the six Directors at the 2018 Annual Meeting. The Board expects all nominees to attendDecember 31, 2019 contained in the Annual Meeting.

The affirmative voteinformation set forth under the caption "Annex I - Summary Financial Information" is incorporated herein by reference.

This Proxy Statement, Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 are available for viewing, printing and downloading at www.meditech.com/shareholder/reports.html. In addition, copies of the holders of a plurality of the shares of common stock present or represented by proxyAnnual Report on Form 10-K and voting at the Annual MeetingQuarterly Report on Form 10-Q will be requiredfurnished without charge to elect each of the nominees as a Director. If you vote for specific nominees rather than all of them, your vote will count for only those selected. You may withhold authorityany shareholder upon written request to vote for the nominees by indicating "NONE OF THE ABOVE" on your Proxy Page, in which case your vote will not count for any nominee. Each of the nominees has agreed to serve as a Director if elected, and MEDITECH has no reason to believe any nominee will be unable to serve. However, if any nominee should become unavailable, your shares will, to the extent they were to be voted in favor of such nominee, be voted for another nominee, if any, proposed by the Board.

MEDITECH Shareholders may send communications to the full Board or to specific Directors in care of Shannon M. Connell, Secretary, Medical Information Technology, Inc., MEDITECH Circle, Westwood MA 02090. The Secretary will forward copies of such communications directly toThis Proxy Statement, Annual Report on Form 10-K and Quarterly Report on Form 10-Q are also available on the full Board or to specific Directors as requested.SEC's website at www.sec.gov.

Page 4The book value per share of 13Common Stock as of September 30, 2020 was $14.45.

Below is a list of all Directors are elected each year at the Annual Meeting of Shareholders. Alland Executive Officers are elected at the first meeting of the Board following the Annual Meeting of Shareholders and hold office for one year. The positions held by each Director and Officer of MEDITECH on March 23, 2018, are shown below. There are no family relationships among the following persons.as of [DATE].

The address of all Directors and Executive Officers and Directors is in care of Medical Information Technology, Inc., MEDITECH Circle, Westwood, MA 02090. The following is a description of the business experience during the past five years of each Director and Executive Officer.

A. Neil Pappalardo, the founder and Chairman of MEDITECH, was its Chief Executive Officer until 2010, and has been a Director since 1969.

Lawrence A. Polimeno has been the Vice Chairman of MEDITECH since 2002, was its President and Chief Operating Officer prior to that, has been a Director since 1985, and has been with MEDITECH since 1969.

Howard Messing has been the President and Chief Executive Officer of MEDITECH since 2010,2019, was its President and Chief OperatingExecutive Officer prior to that, has been a Director since 2011, and has been with MEDITECH since 1974.

Barbara A. Manzolillo has been a Director since 2016, is the Treasurer and Chief Financial Officer since 1996, was the Treasurer prior to that, has been a Director since 2016, and has been with MEDITECH since 1975.

Edward B. Roberts, co-founder of MEDITECH, is the David Sarnoff Professor of Management of Technology at the Sloan School of Management at the Massachusetts Institute of Technology, and has been a Director since 1969.

Stuart N. Lefthes has been a Director since 2016, retired as the Senior Vice President of Sales inEmeritus since 2016, was a Senior Vice President prior to that, has been a Director since 2016, and had been with MEDITECH since 1983.

Michelle I. O'Connor has been the President and Chief Operating Officer since 2019, was Executive Vice President and Chief Operating Officer since 2016, was Executive Vice President of Product Development prior to that, and has been with MEDITECH since 1988.

Hoda Sayed-Friel has been thean Executive Vice President of Strategy and Client Services since 2012, was thea Vice President of Marketing prior to that, and has been with MEDITECH since 1986.

Helen M. Waters has been thean Executive Vice President of Sales and Marketing since 2016, was a Vice President of Customer Service prior to that, and has been with MEDITECH since 1990.

Steven B. Koretz has been the Senior Vice President of Client Services since 2012, was a Vice President prior to that, and has been with MEDITECH since 1982.

Scott M. Radner has been the Vice President of Technology since 2011, was a Senior Manager prior to that, and has been with MEDITECH since 1990.

James W. MerlinNeither MEDITECH nor, to MEDITECH's knowledge, any of MEDITECH's Directors or Executive Officers has been convicted in a criminal proceeding during the Controller and Chief Accounting Officer since 2016, was the Controller prior to that, andpast five years (excluding traffic violations or similar misdemeanors) or has been with MEDITECH since 1986.a party to any judicial or administrative proceeding during the past five years (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.

The BoardEach of MEDITECH's Directors oversees MEDITECH's business and financial activities and monitors the performance of management, butExecutive Officers is not involved in the day-to-day operations. The Directors review MEDITECH's performance, processes and controls, key policies, legal and regulatory requirements, ethical conduct and new or unusual transactions. The Directors are actively involved in oversight of business and financial risks which could affect MEDITECH. The Board receives regular quarterly reports from Officers which cover topics such as financial, technological, regulatory and reputation risk. The Directors meet regularly with the CEO, the CFO, other Officers; read reports and other materials; and participate in Board and committee meetings. The Board consists of 6 members. During 2017 the Board held 4 regularly scheduled quarterly meetings and a quorum was present at each meeting. Messrs. Roberts and Lefthes are "independent" as defined by the rulescitizen of the NYSE and NASDAQ.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND MANAGEMENTEXECUTIVE OFFICERS

The following table provides information as of March 23, 2018[DATE] with respect to the shares of common stock beneficially owned by (i) each person known by MEDITECHto us to own beneficially more than 5%five percent of MEDITECH'sthe outstanding common stock,shares of our Common Stock and (ii) each Director and Executive Officer of MEDITECH each Executive Officer named in the Compensation Table and by all Directors and Officers of MEDITECH as a group.their respective associates. The number of shares beneficially owned is determined according to rules of the Securities and Exchange Commission. Under such rules, a person's beneficial ownership includes any shares as to which such person has sole or shared voting power or investment power.

*The number of shares indicated for Mr. Pappalardo includes the shares owned by the MEDITECH Profit Sharing Trust. Mr. Pappalardo is the sole Trustee of the MEDITECH Profit Sharing Trust and therefore has the power to vote its shares in addition to his own 9,900,7549,915,954 shares. Likewise the number of shares indicated for the 14 Directors and Officers as a Group includes the shares owned by the MEDITECH Profit Sharing Trust.

During 2017,MEDITECH shareholders may communicate with the full Board or specific Directors by sending postal mail to Shannon M. Connell, Secretary, Medical Information Technology, Inc., MEDITECH Profit Sharing Trust filed Forms 4 for its purchases of MEDITECH stock, but some of these filings were late. To MEDITECH's knowledge, based solely on a review ofCircle, Westwood MA 02090 or by emailing sconnell@meditech.com. The Secretary will then forward such communications directly to the reports given to MEDITECH, all other Section 16(a) filing requirements applicable to its Executive Officers, Directors and greater-than-10% shareholders were satisfied in 2017.

Thefull Board of Directors has selected Wolf & Company as MEDITECH's Independent Registered Public Accounting Firm for the year ending December 31, 2018. The Board does not expect a representative of Wolf & Company to be present at the meeting.

During 2017, audit and non-audit services included auditing MEDITECH's financial statements, reviewing unaudited quarterly financial information, and discussing various accounting, tax, and regulatory matters. Fees paid or to be paid for such services for the three years ended December 31 arespecific Directors as follows:

It is the policy of the Board of Directorsrequested. Please email questions early to approve all audit and non-audit services to be provided to MEDITECH by its Independent Registered Public Accounting Firm and the above amounts were so approved.ensure a timely response.

SHAREHOLDER PROPOSALS TO BE SUBMITTED AT THE NEXT ANNUAL MEETING

The Board of Directors carefully considers all proposals and suggestions from Shareholders. When adoptionIf the Reverse Stock Split is in the best interest of MEDITECH and its Shareholders, and can be accomplished without Shareholder approval, the proposal will be implemented without inclusion in the proxy material or presentation to Shareholders for consideration at the Annual Meeting.

Shareholdernot completed, shareholder proposals submitted for inclusion in MEDITECH's Proxy Statement and Proxy Page for next year's Annual Meeting must be received by MEDITECH at its corporate offices on or before November 23, 2018[DATE] and must comply with the rules of the SEC governing the form and content of such proposals, in order to be considered for inclusion in MEDITECH's Proxy Statement and Proxy Page. Any such proposals should be directed to Shannon M. Connell, Secretary, Medical Information Technology, Inc., MEDITECH Circle, Westwood MA 02090.

By Order of the Board of Directors,

Shannon M. Connell, Secretary
Westwood, Massachusetts
March 23, 2018October [DATE], 2020

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

THE BOARD UNANIMOUSLY RECOMMENDS SHAREHOLDERS VOTE FOR ALL SIX NOMINEES LISTED UNDER PROPOSAL 1 AND VOTE FOR PROPOSAL 2.IN FAVOR OF THE PROPOSAL. SHARES WILL BE SO VOTED UNLESS OTHERWISE INDICATED. IF NO SELECTION IS MADE, THE PROXIES WILL VOTE ABSTAIN AS YOUR VOTE.

[X] PLEASE MARK VOTES AS IN THIS EXAMPLE.

1. To electamend MEDITECH's Articles of Organization to effect a reverse split of the following nominees as the six Directorsauthorized and outstanding common stock, par value $1.00 per share, of MEDITECH to serve until the 2019 Annual Meetingin a ratio of Shareholders and thereafter until their successors are chosen and qualified:

2. To ratify the selection of Wolf & Company as MEDITECH's Independent Registered Public Accounting Firm1 for the fiscal year ending December 31, 2018:5,000.

[ ] FOR
[ ] AGAINST
[ ] ABSTAIN

Please be sure to sign and date this Proxy Page. The undersigned Shareholder authorizes theshareholder hereby revokes all prior proxies and appoints [*] proxies to represent and vote on the above matters as indicated and to vote, in their discretion, upon such other matters as may properly come beforeat the AnnualSpecial Meeting or any adjournments or postponements thereof.

NAME OF SHAREHOLDER: ___________________________________________________________________________________________

NUMBER OF SHARES AS OF MARCH 23, 2018: ___________________________[*]: ____________________________

SIGNATURE: ________________________________ ___________________________________

DATE: ________________